Insufficient scRNA-seq data for expression of CCDC134 at single-cell level.
Insufficient scRNA-seq data for expression of CCDC134 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 99% | 96.58 | 1427 / 1445 | 99% | 10.26 | 181 / 183 |
lung | 100% | 131.33 | 576 / 578 | 98% | 8.17 | 1131 / 1155 |
intestine | 100% | 107.20 | 963 / 966 | 97% | 6.56 | 509 / 527 |
skin | 100% | 168.86 | 1807 / 1809 | 96% | 8.62 | 454 / 472 |
stomach | 99% | 112.88 | 356 / 359 | 97% | 7.81 | 277 / 286 |
prostate | 100% | 100.40 | 245 / 245 | 95% | 5.79 | 477 / 502 |
breast | 99% | 99.38 | 453 / 459 | 96% | 6.98 | 1074 / 1118 |
uterus | 99% | 95.74 | 169 / 170 | 94% | 6.45 | 430 / 459 |
pancreas | 100% | 107.70 | 328 / 328 | 93% | 4.22 | 165 / 178 |
bladder | 100% | 95.33 | 21 / 21 | 89% | 5.15 | 449 / 504 |
kidney | 100% | 147.10 | 89 / 89 | 89% | 5.85 | 798 / 901 |
thymus | 100% | 130.95 | 652 / 653 | 88% | 4.24 | 534 / 605 |
ovary | 99% | 82.57 | 178 / 180 | 88% | 4.82 | 378 / 430 |
brain | 88% | 63.47 | 2323 / 2642 | 95% | 5.46 | 672 / 705 |
adrenal gland | 100% | 565.66 | 258 / 258 | 77% | 5.47 | 176 / 230 |
liver | 99% | 85.18 | 223 / 226 | 54% | 2.14 | 220 / 406 |
spleen | 100% | 165.83 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 10.33 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.01 | 1 / 1 |
muscle | 99% | 94.80 | 795 / 803 | 0% | 0 | 0 / 0 |
adipose | 99% | 79.14 | 1189 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 73.86 | 1304 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 178.17 | 879 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 6.01 | 27 / 29 |
heart | 90% | 64.22 | 777 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 3.28 | 66 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001525 | Biological process | angiogenesis |
GO_0021591 | Biological process | ventricular system development |
GO_0030278 | Biological process | regulation of ossification |
GO_1990402 | Biological process | embryonic liver development |
GO_0035162 | Biological process | embryonic hemopoiesis |
GO_0001890 | Biological process | placenta development |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | CCDC134 |
Protein name | Coiled-coil domain-containing protein 134 Coiled-coil domain containing 134 |
Synonyms | |
Description | FUNCTION: In extracellular secreted form, promotes proliferation and activation of CD8(+) T cells, suggesting a cytokine-like function . Enhances cytotoxic anti-tumor activity of CD8(+) T cells . May inhibit ERK and JNK signaling activity . May suppress cell migration and invasion activity, via its effects on ERK and JNK signaling . Has a critical role in the regulation of osteogenesis and bone development . .; FUNCTION: In the nucleus, enhances stability of the PCAF histone acetyltransferase (HAT) complex member TADA2A and thus promotes PCAF-mediated H3K14 and H4K8 HAT activity. May inhibit TADA2A-mediated TP53/p53 'Lys-321' acetylation, leading to reduced TP53 stability and transcriptional activity. May also promote TADA2A-mediated XRCC6 acetylation thus facilitating cell apoptosis in response to DNA damage. . |
Accessions | B0QY51 Q9H6E4 ENST00000255784.6 ENST00000402061.7 |